Penumbra Inc. (PEN) shares skyrocketed 19.36% in pre-market trading on Thursday, as investors reacted to a series of positive analyst reports and the company's strong third-quarter performance. The medical device manufacturer, known for its innovative stroke and vascular products, has become one of the top pre-market movers, signaling renewed investor confidence in its growth prospects.

The surge in Penumbra's stock price comes on the heels of multiple price target upgrades from prominent Wall Street analysts. Leerink Partners raised its target price to $332 from $327, while Truist Securities increased its target to $312 from $300. JP Morgan and Jefferies also joined the bullish chorus, lifting their price targets to $275 and $335, respectively. These upgrades reflect growing optimism about Penumbra's market position and future potential in the medical technology sector.

Adding to the positive sentiment, William Blair analyst Brandon Vazquez maintained a Buy rating on Penumbra stock, citing the company's strong Q3 performance and future growth catalysts. This wave of analyst enthusiasm, combined with Penumbra's solid financial results, has propelled the stock to outperform in a generally positive pre-market session. As U.S. stock markets prepare to open, investors will be closely watching Penumbra to see if this significant pre-market gain translates into sustained momentum throughout the trading day.